All In Biotech

Drug Trial Radar · NCT05902962

SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects

A Phase 1 Open-Label, Single Arm Dose Escalation Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy

Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

17

Actual

Start

Apr 20, 2023

Primary completion

Aug 8, 2025

Study completion Aug 8, 2025

Sponsor

Lead sponsor
PYC TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1 Open-Label, Single Arm Dose Escalation Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy

Conditions

  • Retinal Dystrophy
  • PRPF31 Mutationassociated Retinal Dystrophy
  • RP11

Interventions

  • VP-001Drug

    Phase 1 open-label, single arm dose escalation study of VP-001 in participants with genetically confirmed PRPF31 mutation-associated retinal dystrophy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence, severity, and relatedness of treatment-emergent ocular adverse events (TEAEs) and treatment-emergent serious adverse events (TE-SAEs) in the study eyeTime frame: over a 24-week time period
  2. The incidence, severity, and relatedness of treatment-emergent ocular adverse events (TEAEs) and treatment-emergent serious adverse events (TE-SAEs) in the study eyeTime frame: over a 48-week time period

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • University of Florida Health

    Jacksonville, Florida

  • Bascom Palmer Eye Institute University of Miami

    Miami, Florida

  • University of Michigan Kellogg Eye Center

    Ann Arbor, Michigan

  • Oregon Health and Science University - Casey Eye Institute

    Portland, Oregon

  • Retina Foundation of the Southwest

    Dallas, Texas

  • Baylor College of Medicine- Alkek Eye Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.